Form 4: ALX Oncology CEO Jason Lettmann Acquires 4,400 Shares of Common Stock
SEC Form 4
ALX Oncology's CEO, Jason Lettmann, recently purchased 4,400 shares of the company's common stock at a price of $11.3117 per share.
Summary
- On March 14, 2024, Jason Lettmann, the CEO of ALX Oncology Holdings Inc. (ALXO), acquired 4,400 shares of common stock.
- The purchase price was $11.3117 per share.
- Following the transaction, Lettmann directly owns 171,620 shares of ALX Oncology.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by the CEO. While insider buying can be seen as a positive signal, it's not overwhelmingly positive without additional context.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive sign, potentially increasing investor confidence.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of the transaction where Jason Lettmann acquired 4,400 shares of ALX Oncology common stock. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.